Annexon

ANNX50

$5.75arrow_drop_down1.20%-$0.07

ANNX50

$5.75

arrow_drop_down1.20%-$0.07

Performance History

Key Stats
Open	$5.85
Prev. Close	$5.82
EPS	-1.21
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	5.53	6.00
52 Week Range	1.57	8.40

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.21

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Annexon (ANNX)

Annexon, Inc. (ANNX) is a biopharmaceutical company that focuses on the development of therapeutics for neurodegenerative disorders and diseases of the complement pathway. The company is dedicated to transforming the treatment of these conditions by targeting the root cause of the diseases rather than just managing the symptoms. Annexon's innovative approach involves the selective inhibition of the classical complement pathway, a key component of the immune system that plays a vital role in the progression of many neurodegenerative disorders.

One of Annexon's leading drug candidates is ANX005, a monoclonal antibody that specifically targets C1q, the initiating molecule of the classical complement pathway. By inhibiting C1q, ANX005 has the potential to disrupt the complement cascade and prevent the activation of downstream complement components. This approach has shown promising results in preclinical studies and has the potential to provide a novel therapeutic option for patients with neurodegenerative disorders such as Alzheimer's disease and Huntington's disease.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Douglas Love Esq., J.D.
Headquarters: Brisbane
Employees: 77
Exchange: NASDAQ

Keep an eye on Annexon

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Annexon's (ANNX) price per share?

The current price per share for Annexon (ANNX) is $5.75. The stock has seen a price change of -$0.07 recently, indicating a -1.2% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Annexon (ANNX)?

For Annexon (ANNX), the 52-week high is $8.4, which is 46.09% from the current price. The 52-week low is $1.57, the current price is 266.24% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Annexon (ANNX) a growth stock?

Annexon (ANNX) has shown an average price growth of 0.41% over the past three years. It has received a score of 56 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Annexon as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Annexon (ANNX) stock price performance year to date (YTD)?

As of the latest data, Annexon (ANNX) has a year-to-date price change of 18.8%. Over the past month, the stock has experienced a price change of 1.41%. Over the last three months, the change has been -2.38%. Over the past six months, the figure is 9.73%.

help

Is Annexon (ANNX) a profitable company?

Annexon (ANNX) has a net income of -$134.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$143.72M. Furthermore, the EBITDA is -$124.79M.

help

What is the market capitalization of Annexon (ANNX)?

Annexon (ANNX) has a market capitalization of $615.97M. The average daily trading volume is 802.56K, indicating the stock's liquidity and investor engagement.

News

ANNEXON

ANX007

GEOGRAPHIC ATROPHY

DRY AGE-RELATED MACULAR DEGENERATION

PHASE 2 ARCHER TRIAL

7/11/2024

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting - GlobeNewswire